Pre-Open Stock Movers

Baudax Bio, Inc. (NASDAQ: BXRX) 31.7% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for ANJESO (meloxicam injection), which is indicated for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.

TrueCar (NASDAQ: TRUE) 28.9% LOWER; reported Q4 EPS of ($0.01), $0.03 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $89.7 million versus the consensus estimate of $88.05 million. TrueCar sees Q1 2020 revenue of $87-89 million, versus the consensus of $86.92 million. TrueCar sees FY2020 revenue of $335-355 million, versus the consensus of $367.46 million.

California Resources Corporation (NYSE: CRC) 28.2% HIGHER; announced the commencement of private offers to exchange (the “Exchange Offers”), upon the terms and conditions set forth in the offering memorandum and solicitation statement (the “Offering Memorandum and Solicitation Statement”), dated February 20, 2020, and the related letter of transmittal, to all Eligible Holders (as defined below) of its outstanding 8% Senior Secured Second Lien Notes due 2022 (the “8% Notes”), 5½% Senior Notes due 2021 (the “5½% Notes”) and 6% Senior Notes due 2024 (the “6% Notes” and, together with the 8% Notes and the 5½% Notes, the “Notes”) to exchange the outstanding Notes, subject to the Acceptance Priority Level.

BlueLinx Holdings Inc. (NYSE: BXC) 28% LOWER; responded to a press release issued by an investment firm that goes by the name of Bluefin Acquisitions, LLC. In its press release, Bluefin Acquisitions claimed that it was making a tender offer to acquire at least 35% of the Company’s common stock at a price of $24.50 per share. The Company was not aware of this purported offer. Upon learning of the press release and not being able to verify that it was a legitimate offer, the NYSE halted trading in the Company’s stock for the remainder of the trading day. We expect that trading will resume tomorrow, February 21, when the market opens. The Company is not able to assess the validity of the purported offer. The Company believes that the purported offeror’s actions may be false and misleading in violation of the U.S. securities laws because they failed to comply with the filing and disclosure requirements.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) 18.5% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

DMC Global (NASDAQ: BOOM) 18% LOWER; reported Q4 EPS of $0.65, $0.20 better than the analyst estimate of $0.45. Revenue for the quarter came in at $86.4 million versus the consensus estimate of $83.61 million.

Livent Corporation (NYSE: LTHM) 15.7% LOWER; reported Q4 EPS of $0.05, in-line with the analyst estimate of $0.05. Revenue for the quarter came in at $78 million versus the consensus estimate of $82.01 million.

ZixCorp (NASDAQ: ZIXI) 15.1% HIGHER; reported Q4 EPS of $0.13, in-line with the analyst estimate of $0.13. Revenue for the quarter came in at $50.4 million versus the consensus estimate of $49.55 million. ZixCorp sees Q1 2020 EPS of $0.12-$0.13, versus the consensus of $0.12. ZixCorp sees Q1 2020 revenue of $52.2-52.7 million, versus the consensus of $50.23 million. ZixCorp sees FY2020 EPS of $0.56-$0.58, versus the consensus of $0.56. ZixCorp sees FY2020 revenue of $220-225 million, versus the consensus of $211.41 million.

First Solar (NASDAQ: FSLR) 14.2% LOWER; reported Q4 EPS of $1.48, $1.24 worse than the analyst estimate of $2.72. Revenue for the quarter came in at $1.4 billion versus the consensus estimate of $1.75 billion.

eHealth (NASDAQ: EHTH) 13.8% HIGHER; reported Q4 EPS of $4.13, $1.70 better than the analyst estimate of $2.43. Revenue for the quarter came in at $301.7 million versus the consensus estimate of $234.86 million. eHealth sees FY2020 EPS of $3.56-$4.09, versus the consensus of $3.01. eHealth sees FY2020 revenue of $580-620 million, versus the consensus of $546.02 million.

Dropbox (NASDAQ: DBX) 13.5% HIGHER; reported Q4 EPS of $0.16, $0.02 better than the analyst estimate of $0.14. Revenue for the quarter came in at $446 million versus the consensus estimate of $443.41 million.

Agile Therapeutics, Inc. (Nasdaq: AGRX) 13.4% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

Conduent Incorporated (NASDAQ: CNDT) 12.1% LOWER; reported Q4 EPS of $0.18, $0.02 worse than the analyst estimate of $0.20. Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $1.08 billion.

Zscaler (NASDAQ: ZS) 11% LOWER; reported Q2 EPS of $0.09, $0.06 better than the analyst estimate of $0.03. Revenue for the quarter came in at $101.3 million versus the consensus estimate of $98.97 million. Zscaler sees Q3 2020 EPS of $0.01-$0.03, versus the consensus of $0.04. Zscaler sees Q3 2020 revenue of $105-107 million, versus the consensus of $104.6 million. Zscaler sees FY2020 EPS of $0.14-$0.16, versus the consensus of $0.15. Zscaler sees FY2020 revenue of $414-417 million, versus the consensus of $410.38 million.

Ducommun Inc. (NYSE: DCO) 10% HIGHER; reported Q4 EPS of $0.80, $0.15 better than the analyst estimate of $0.65. Revenue for the quarter came in at $186.9 million versus the consensus estimate of $184.58 million.

National CineMedia (NASDAQ: NCMI) 8% HIGHER; reported Q4 EPS of $0.24, $0.03 better than the analyst estimate of $0.21. Revenue for the quarter came in at $147.2 million versus the consensus estimate of $140.08 million. National CineMedia sees FY2020 revenue of $450-465 million, versus the consensus of $452.53 million.

GENFIT (Nasdaq: GNFT) 7.8% LOWER; today announced that unblinding of the Phase 3 RESOLVE-IT data will be delayed to incorporate the latest FDA insights expected by the end of March. Topline interim results will be announced in the weeks following receipt of FDA insight.

BioSig Technologies, Inc. (Nasdaq: BSGM) 7.8% LOWER; announced that it intends to offer shares of its common stock in a 'best efforts' underwritten public offering.

Schrodinger Inc. (NASDAQ: SDGR) 7.6% HIGHER; adds to gains of 33% on Thursday after Citron Research called it an "early state Tesla."

Texas Roadhouse (NASDAQ: TXRH) 7.2% HIGHER; reported Q4 EPS of $0.61, $0.09 better than the analyst estimate of $0.52. Revenue for the quarter came in at $725.2 million versus the consensus estimate of $714.04 million. Comparable restaurant sales increased 4.4% at company restaurants and 3.4% at domestic franchise restaurants.

Builders FirstSource (NASDAQ: BLDR) 7% LOWER; reported Q4 EPS of $0.40, $0.05 better than the analyst estimate of $0.35. Revenue for the quarter came in at $1.8 billion versus the consensus estimate of $1.76 billion.

Slack (NYSE: WORK) 6.7% HIGHER; reports from Business Insider that Uber (NYSE: UBER) is moving all of its 38,000 employees to Slack.

Deere & Co. (NYSE: DE) 6.2% HIGHER; reported Q1 EPS of $1.63, $0.37 better than the analyst estimate of $1.26. Revenue for the quarter came in at $7.63 billion versus the consensus estimate of $6.42 billion.

AVX Corporation (NYSE: AVX) 5.5% HIGHER; announced today that Kyocera Corporation and AVX have entered into a definitive merger agreement providing for the acquisition by Kyocera of all the outstanding shares of common stock of AVX not owned by Kyocera pursuant to an all-cash tender offer for $21.75 per share (the Tender Offer), followed by a squeeze-out merger in which all of the outstanding shares of AVX common stock not tendered in the Tender Offer (other than shares owned by holders who validly seek appraisal or shares already held by Kyocera) will be converted into the right to receive $21.75 per share of common stock, in cash (the Transaction). Kyocera currently owns approximately 72% of the outstanding shares of AVX common stock. Following completion of the Transaction, AVX will become a wholly owned subsidiary of Kyocera.

Nabors Industries (NYSE: NBR) 5.3% LOWER; reported Q4 EPS of ($0.77), $0.50 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $715.77 million versus the consensus estimate of $746.11 million.

Globant (NYSE: GLOB) 5% HIGHER; reported Q4 EPS of $0.64, $0.03 better than the analyst estimate of $0.61. Revenue for the quarter came in at $184.3 million versus the consensus estimate of $183.16 million. Globant sees Q1 2020 EPS of at least $0.62, versus the consensus of $0.60. Globant sees Q1 2020 revenue of at least $188 million, versus the consensus of $181.84 million. Globant sees FY2020 EPS of at least $2.74, versus the consensus of $2.74. Globant sees FY2020 revenue of at least $810 million, versus the consensus of $809.41 million.

Sprouts Farmers Market (NASDAQ: SFM) 5% HIGHER; reported Q4 EPS of $0.27, $0.14 better than the analyst estimate of $0.13. Revenue for the quarter came in at $1.4 billion versus the consensus estimate of $1.36 billion. Sprouts Farmers Market sees Q1 2020 EPS of $0.45-$0.47, versus the consensus of $0.46. Sprouts Farmers Market sees FY2020 EPS of $1.17-$1.23, versus the consensus of $1.12.

Chewy Inc. (NYSE: CHWY) 4.8% HIGHER; RBC Capital upgraded from Sector Perform to Outperform with a price target of $38.00.

Weight Watchers International (NASDAQ: WW) 4.2% HIGHER; DA Davidson upgraded from Neutral to Buy and raises its price target to $56 (from $33)

Celldex Therapeutics (NASDAQ: CLDX) 4% HIGHER; Cantor Fitzgerald initiates coverage on with a Overweight rating and a price target of $8.00.

Boyd Gaming (NYSE: BYD) 3.8% LOWER; reported Q4 EPS of $0.50, versus analyst estimate of $0.47. Revenue for the quarter came in at $833.1 million versus the consensus estimate of $825.64 million. Total Adjusted EBITDAR(1) was $227.6 million in the fourth quarter of 2019, up 9.1% from $208.6 million in the fourth quarter of 2018.

GoPro (NASDAQ: GPRO) 2.5% HIGHER; Korr Acquisitions sent a letter to GoPro (NASDAQ: GPRO), saying the stock could be worth $9.49-$14.97 per share to a buyer. The firm urged the company to explore strategic alternatives.